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In the era of precision medicine, the tailoring of cancer treatment is increasingly
important as we transition from organ-based diagnosis towards a more comprehen-
sive and patient-centric molecular diagnosis. This is particularly the case for high-
grade serous adenocarcinomas of the ovary and peritoneum, which are commonly
diagnosed at an advanced stage, and collectively treated and managed similarly. We
characterized the N- and O-glycome of serous ovarian (OC) and peritoneal cancer
(PC) tissues using PGC-LC-ESI-IT-MS/MS profiling and validated the discriminatory
glycans and their corresponding glyco-gene expression levels using cell lines and tran-
scriptomic data from 232 patients. Overall, the N- and O-glycan repertoires of both
cancer types were found to comprise mostly of a2,6-sialylated glycan structures, with
the majority of N-glycans displaying the biantennary mono- and disialylation as well
as bisecting-type biantennary glycans. The MS profiling by PGC-LC also revealed
several glycan structural isomers that corresponded to LacdiNAc-type (GalNAcb1-
4GlcNAc) motifs that were unique to the serous ovarian cancers and that correlated
with elevated gene expression of B4GALNT3 and B4GALNT4 in patients with serous
cancer. Statistical evaluation of the discriminatory glycans also revealed 13 N- and 3
O-glycans (P < 0.05) that significantly discriminated tumour-sampling sites, with
LacdiNAc-type N-glycans (m/z 1205.02 and m/z 1059.42) being associated with
ovarian-derived cancer tissue and bisecting GlcNAc-type (m/z 994.92) and branched
N-glycans (m/z 1294.02 and m/z 1148.42) upregulated at the metastatic sites. Hence,
we demonstrate for the first time that OC and PC display distinct molecular signatures
at both their glycomic and transcriptomic levels. These signatures may have potential
utility for the development of accurate diagnosis and personalized treatments.
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BPC, base peak chromatogram; EIC, extracted ion chromatogram; ESI, electrospray ionization; FIGO, International Federation of Gynecology
and Obstetrics; Fuc, L-fucose; Gal, D-galactose; GalNAc, N-acetyl-D-galactosamine; Glc, D-glucose; GlcNAc, N-acetyl-D-glucosamine; GLM,
generalized linear model; HGSC, high-grade serous cancer; IT, ion trap; LacdiNAc, N,N0-diacetyl-lactosamine; LC, liquid chromatography;
Man, D-mannose; MS, mass spectrometry; Neu5Ac, N-acetyl-neuraminic acid; OC, high-grade serous ovarian cancer; PC, high-grade serous
peritoneal cancer; PGC, porous graphitized carbon; RF, random forest.
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1. Introduction
Epithelial ovarian cancer has the highest mortality rate
of all gynaecological malignancies, because more than
75% of tumours are diagnosed at an advanced FIGO
(International Federation of Gynecology and Obstet-
rics) stage (III and IV) (Coleman et al., 2011) where
the 5-year survival rate is only 20% (Fishman and
Bozorgi, 2002; Ozols, 2006). Compared to many other
solid cancer types, the prognosis for ovarian cancer
has changed little since platinum-based treatment was
introduced more than 30 years ago (Vaughan et al.,
2011). Epithelial ovarian cancer is a heterogeneous
group of cancers, classified primarily on their
histopathological features (serous being the most com-
mon subtype) and location of the primary tumour
mass (Kurman and Shih Ie, 2010; Scully et al., 1998).
Serous ovarian and peritoneal tumours are believed to
be frequently derived from the fallopian tube, may not
be distinguishable preoperatively (Barda et al., 2004),
display a similar genetic predisposition (BRCA muta-
tions) (Bandera et al., 1998a,b) and commonly present
with widespread dissemination within the pelvis and
abdomen (Kessler et al., 2013; Seidman et al., 2011).
Despite being treated identically, there is a debate as
to whether these cancers are variants of the same
malignancy or develop through different pathways.
Difficulties in the identification of the site of origin in
patients with advanced disease, where the ovary, fal-
lopian tube and the abdominal cavity are all usually
involved, plus their macroscopic and microscopic
resemblance, are major causes of this debate.
Recent findings suggest that peritoneal and ovarian
cancer may be linked to different carcinogenic path-
ways, with both cancers exhibiting differences in pro-
tein expression of Her2/neu, estrogen and progesterone
receptors (Sorensen et al., 2015). This is in line with
elevated plasma levels of the routinely used clinical
biomarkers, HE4 and CA125, in peritoneal compared
to ovarian and tubal cancers (Jacob et al., 2011).
There is also increasingly epidemiological evidence that
peritoneal cancer and ovarian cancer are two distinct
diseases (Gao et al., 2016; Rottmann et al., 2017; Sch-
nack et al., 2014). It is evident that studies investigat-
ing the underlying differences within these serous
cancer subtypes which are reflective of the individual
cellular phenotypes and molecular origin have been
rather limited (Chen et al., 2003; Lacy et al., 1995;
Pere et al., 1998). It has also been shown that a major-
ity of fallopian tubes examined from patients with pri-
mary peritoneal cancer have been found with the
presence of serous tubal intraepithelial lesions, thereby
giving the tumour cells access to the peritoneal cavity
(Seidman et al., 2011). Despite the use of high-
throughput ‘omics’ technologies that are rapidly
increasing, no studies have elucidated the characteristic
molecular profiles of these morphologically related
cancer tissue samples within this context. Specifically,
the degree to which these serous tumours differ,
despite their similarity in terms of pathogenesis, clini-
cal behaviour and chemotherapy response, remains to
be elucidated.
It has been widely established that protein glycosyla-
tion is an important post-translational modification,
which has relevance in many biological processes such
as cell signalling, immune responses, extracellular
interaction and cell adhesion (Cummings and Pierce,
2014). In fact, several studies have elucidated a
plethora of cellular- and in vivo tissue-specific glycan
patterns on glycoproteins, thereby providing an insight
into the specificity of glycosylation activities (Chan-
drasekaran et al., 2006; Sun et al., 2011). In the
tumour microenvironment, aberrant glycosylation has
been well documented, with increasing evidence point-
ing to the role of N- and O-glycans in modulating crit-
ical aspects of tumour growth and development as well
as metastasis. These structures resemble molecular-
level glycomic ‘fingerprints’ which facilitate the dis-
crimination between healthy and diseased states or
reflect tumour microheterogeneity caused by the varia-
tion within cancer subtypes (Abbott et al., 2010; Chris-
tiansen et al., 2014; West et al., 2010). While several
studies yielded clinically relevant information on the
differential expression of ovarian cancer-associated gly-
cans found in patients’ serum and tissues, the major
focus of their analysis was on differentiating between
healthy and diseased patients (Abbott et al., 2008;
Jacob et al., 2012, 2014a). In regard to cell surface gly-
cosylation, there is still a lack of studies that have uti-
lized glycomics to characterize the specific N- and
O-glycan structures within the serous-histotype groups
of tumours which likely represent distinct diseases
despite still being classified as ovarian cancer.
To address this challenge, we have employed a
quantitative MS-based glycomics profiling of plasma
membrane N- and O-glycoproteins derived from inva-
sive adenocarcinomas of the ovary and peritoneum.
We also sought to identify specific glycotopic features
of these serous cancer tissues using porous graphitized
carbon (PGC) chromatographic retention and mass
spectrometric fragmentation characteristics, and to val-
idate the presence of discriminatory glycans using a
combination of statistical classification methods and
glyco-gene transcriptomic data derived from an
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independent cohort. This comprehensive tissue glycan
profiling serves as the first step towards identifying ser-
ous cancer glycan biomarkers that may be utilized in
diagnostics or further applied to various MS imaging
technology platforms for the robust and sensitive dis-
crimination of tumours.
2. Results
Specimens used in this study were diagnosed by pathol-
ogists as either high-grade serous ovarian cancer (OC)
or peritoneal cancer (PC) based on their corresponding
histopathological features. The membrane proteins
were extracted from these tissues and the released N-
and O-glycan alditols were analysed using negative ion
mode PGC-LC-ESI-MS/MS, which resulted in the
detection of well-resolved chromatographic peaks that
corresponded to specific glycan structures (Everest-
Dass et al., 2013a,b). Upon the identification of char-
acteristic glycan features for each serous cancer type,
glycan structural profiles were subjected to a series of
statistical evaluations to potentially distinguish between
serous ovarian and peritoneal cancers. For some of the
tissue samples that were analysed, the diagnosis did not
correspond to the location from which the tissue was
derived; for example, OC specimen was obtained from
an omental (omentum) metastasis and not from their
corresponding primary cancer location (Table S1).
Therefore, we performed two separate statistical analy-
ses in this study: firstly on tissue samples based on
diagnosis (OC vs. PC) and secondly, based on the site
from where the cancer tissue was derived from (ovary
vs. peritoneum vs. omentum). The workflow employed
in this study is outlined in Fig. 1.
2.1. The N- and O-glycan repertoires of serous
adenocarcinomas
The glycan structures, including their isobaric isomers,
were characterized by their retention time and frag-
ment ions and were quantified based on relative inte-
gration of their extracted ion chromatographic peaks
(Table S2). Their structures were classified into five
major glycan types, namely high mannose, hybrid,
complex neutral, complex sialylated and paucimannose
(Stanley et al., 2009). The representative average
summed MS spectra for N-glycans (Fig. 2A) and
O-glycans (Fig. 2B) were overall similar, with the
majority of the peaks in the global MS profiles of both
serous cancer groups typified by sialylated N-glycans,
which appeared to be comparable in terms of their
relative amounts. Several other peaks comprising neu-
tral and high mannose-type glycans were also
observed, appearing at lower intensities. In total, 55
Fig. 1. Graphic illustration of workflow employed in the extraction, profiling and analysis of N- and O-glycans of high-grade serous cancers.
Briefly, membrane proteins were extracted from serous cancers and released N- and O-glycan alditols were separated on porous graphitized
carbon (PGC) and analysed using electrospray ionization mass spectrometry (ESI-IT-MS/MS). Glycans were structurally characterized using
tandem MS and subjected to statistical evaluations to identify discriminatory glycans implicated in the distinction of serous ovarian and
peritoneal cancers. Validation of discriminatory N-glycans and their corresponding glycosyltransferase genes was performed using cell lines
and existing transcriptomic data set derived from a publicly available cohort.
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Fig. 2. Representative average MS glycomic profiles of N- and O-glycans released from membrane proteins of serous cancer tissues. (A)
An overview of the representative average MS N-glycan profiles in the range of m/z 640–1540 of serous ovarian (S75) and serous peritoneal
(S164) cancers (LC elution time: 30–70 min). Structures were depicted according to the Essentials of Glycobiology notation (Varki et al.,
2015) with linkage placement for sialic acid and fucose residues (where known). The N-glycan structures were identified by tandem MS and
are represented mainly by the doubly charged species ion, m/z [M-2H]2. Glycan masses containing isomeric structures that were resolved
using retention time differences were indicated by asterisks (*). (B) Representative average MS O-glycan profiles in the range of m/z 640–
1340 of serous ovarian (S102) and serous peritoneal (L11) cancers (LC elution time: 30–50 min). The O-glycan structures were identified by
tandem MS and are represented mainly by the singly charged species ion, m/z [M-H]1.
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distinct N- and nine O-glycan masses were identified
(Table S2) across both serous cancers (OC, n = 14 and
PC, n = 14) at varying relative abundance. The struc-
tures were characterized in detail based on their speci-
fic features: (a) sialylation was a major N-glycan
feature in both cancer types, ranging between 66.323
and 68.545% of the total N-glycan structures charac-
terized across all samples. Sialylated N-glycans were
further classified based on the number of sialic acid
residues, in which mono-, di- and trisialylated N-gly-
cans were all observed to be present (Fig. S1A,B). The
four most abundant glycans comprised monosialylated
(m/z 965.92 and m/z 1038.92) and disialylated (m/z
1111.52 and m/z 1184.52) N-glycans in both cancers
(Table S2). Likewise, for the O-glycans, mono- and
disialylation was also a prominent feature in both OC
and PC cancers. Specifically, core 1 structures with
m/z 675.31 [(Neu5Ac)1(Gal)1(GalNAc)1] and m/z
966.31 [(Neu5Ac)2(Gal)1 (GalNAc)1] comprised over
75% of the total ion abundance of the O-glycans of
OC and PC, respectively (Table S2). Several glycans
with structural isomers corresponding to differences in
sialic acid linkage were also observed for some of the
N-glycan masses. For example, the monosialylated
hybrid and complex-type N-glycans with m/z 945.32
and m/z 965.92, respectively, were found as isomers
with terminal a2-3- or a2-6-linked sialic acid, which
were differentiated based on their chromatographic
retention times (Fig. 3Ai–ii). Likewise, the most abun-
dant disialylated N-glycan with m/z 1111.42 was
found to comprise three structural isomers, in which
the a2,6/a2,6-linked isomeric structure eluted from the
column earlier than the remaining two structural iso-
mers containing a2,6/a2,3- and a2,3/a2,3-linked sialic
acids, respectively (Fig. 3Aiii) (Nakano et al., 2011).
The prominence of a2-6 sialylation on membrane pro-
teins of serous tumours analysed in this study corre-
lates with our previous findings reported for ovarian
cancer cell lines (Anugraham et al., 2014). In total, 10
sialylated N-glycan masses were found to contain these
isomeric structures, in which five of these N-glycans
were monosialylated hybrid structures (m/z 783.32,
m/z 856.32, m/z 864.32, m/z 937.32 and m/z
945.32), with an a2-6 sialyl linkage, accounting for
58.465–59.864% of the total hybrid-type isomeric
structures for both serous cancers (Fig. 3Bi). Likewise,
the remaining five isomeric N-glycans were mono- (m/z
957.82, m/z 965.92 and m/z 1038.92) and disialy-
lated (m/z 1111.42 and m/z 1184.52) complex-type
glycans, which also displayed a2-6 sialylation for
approximately 62.217–67.951% (Fig. 3Bii–iii) of the
total complex-type isomeric structures in both serous
cancer groups.
(b) Biantennary and branched N-glycans – Bianten-
nary N-glycans are formed through the addition of b1-
2-linked GlcNAc (N-acetylglucosamine) residues by the
enzyme GlcNAcT-II on both the a1-3- and a1-6-linked
Man residues of the N-glycan core [(Man)3(GlcNAc)2],
which are typically elongated with a Gal residue to form
an antenna on each arm. The assignment of an antenna
in this study was performed based on the presence of a
complete LacNAc (Gal-GlcNAc) disaccharide. In total,
seven N-glycan compositions corresponding to neutral
and sialylated biantennary N-glycans were observed in
serous cancer tissues, accounting for approximately
53.487–58.587% of the total N-glycans for both OC
and PC cancers (Fig. S1C). In regard to the more highly
branched N-glycan structures that are synthesized by
the enzymes, GlcNAcT-IV and GlcNAcT-V to form
b1-4- and b1-6-linked GlcNAc, respectively, eight tri-
and three tetra-antennary structures were identified
in OC and PC cancers and comprised significantly
lower relative abundance as compared to the bianten-
nary N-glycans (P < 0.0001). These structures ranged
between 4.402% and 5.704% of the total glycans in
both serous ovarian and peritoneal cancers.
(c) Bisecting-type biantennary N-glycans – We also
observed the presence of glycan structures correspond-
ing to bisecting-type biantennary N-glycans. In total,
there were 10 structures, of which several forms were
observed such as the agalactosylated bisecting (m/z
759.92, m/z 840.82 and m/z 913.92), biantennary
bisecting (m/z 921.92 and m/z 994.92), monosialy-
lated biantennary bisecting (m/z 986.52, m/z 1059.42,
m/z 1067.52 and m/z 1140.42) and disialylated
biantennary bisecting (m/z 1286.02) N-glycans that
ranged between 6.782 and 6.894% of the total N-gly-
cans in OC and PC (Fig. S1C). A bisecting-type N-gly-
can is formed when a GlcNAc residue is attached to
the innermost mannose of the N-glycan core by the
action of a specific enzyme, b1-4-N-acetyl-glucosami-
nyltransferase III (GlcNAcT-III), encoded by the
MGAT3 gene. The presence of the ‘bisecting’ GlcNAc
group is characterized by a diagnostic D-221 [203
(mass of bisecting GlcNAc) + 18 (H2O)] cleavage ion
which occurs specifically in the negative ion MS mode.
This ion can be visualized in the MS/MS fragmentation
spectra of biantennary N-glycans as m/z 670.21, which
corresponds to the loss of the GlcNAc residue from the
D ion (mass of six-arm antennae composition and two
remaining branching core Man residues), accompanied
by the loss of a water molecule (Fig. S2A–C). In
Fig. S2D, the D-221 ion was observed as m/z 508.31,
for the agalactosylated N-glycan with m/z 759.92,
thereby corresponding to the mass of GlcNAc-Man-
Man-18- (H2O). We have previously observed
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bisecting-type N-glycans on ovarian cancer cell lines
(SKOV3, IGROV1, A23780 and OVCAR3), but not
on the normal ovarian epithelium cell lines, HOSE 6.3
and HOSE 17.1 (Anugraham et al., 2014), thereby vali-
dating the presence of these structures on serous cancer
tissues, as evidenced in this study.
2.2. Elevated LacdiNAc-type N-glycans in ovarian
cancer
Despite the overall similarity between OC and PC
tissues, a comprehensive MS structural profiling of
individual glycan mass signals revealed various glycan
masses significantly discriminating both cancer types.
In OC samples, five N-glycan compositions corre-
sponding to neutral (m/z 913.92 and m/z 934.42) and
sialylated (m/z 1059.42, m/z 1079.92 and m/z
1205.02) structures were found to contain LacdiNAc
(GalNAcb1-4GlcNAc) motifs, accounting for approxi-
mately 2.775  2.005% of the total N-glycans in OC,
while only 0.1247  1.312% was found in PC tissues
(Table S2, Fig. S3). These LacdiNAc-containing glycan
masses were verified by MS/MS fragmentation pat-
terns that differed from their compositional isomers.
For instance, the N-glycan mass with m/z 913.92 con-
sists of two compositional isomers that were separated
Fig. 3. Representative extracted ion chromatograms (EIC) of mono- and disialylated N-glycans and the corresponding relative abundance for
total and a2-6 sialylation. (A) PGC-LC allows for the separation of a2-6 and a2-3 sialylated N-glycans on the same underlying glycan structure
based on retention time. The representative EICs depicting the separate retention times for isomers with a2-6-linked and a2-3-linked sialic
acids are represented for (i) monosialylated N-glycans, m/z 945.32 [(Neu5Ac)1(Gal)1(GlcNAc)1(Man)2+(Man)3(GlcNAc)2] and (ii) m/z 965.9
2
[(Neu5Ac)1(Gal)2 (GlcNAc)2 + (Man)3(GlcNAc)2] and disialylated N-glycans, (iii) m/z 1111.4
2 [(Neu5Ac)2(Gal)2 (GlcNAc)2 +(Man)3(GlcNAc)2]. (B)
Relative abundance for N number of N-glycans bearing sialylated isomeric structures and the percentage of a2-6 sialylation of these isomers
is displayed for hybrid monosialylated (refer to Table S2: five N-glycans; m/z 783.32, m/z 864.32, m/z 856.32, m/z 937.32 and m/z
945.32) (i), complex monosialylated (three N-glycans; m/z 957.82, m/z 965.92 and m/z 1038.92) (ii) and complex disialylated (two N-
glycans; m/z 1111.42 and m/z 1184.52) (iii) for each serous cancer group. Error bars represent SD of biological replicates [serous ovarian
cancer (n = 14) and serous peritoneal cancer (n = 14)]. N = no. of glycan masses with isomeric structures.
1600 Molecular Oncology 11 (2017) 1595–1615 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Tissue glycomics distinguish serous tumour sites M. Anugraham et al.
by the PGC chromatography. The early-eluting isomer
contained a bisecting-type glycan of the same composi-
tion (Fig. 4i), while the later-eluting isomer displayed
the LacdiNAc motif (Fig. 4ii). The presence of the
LacdiNAc antenna was deduced by the presence of the
B ion at m/z 405.11 and the 1,3A cross-ring cleavage
ion at m/z 465.11. This ion, also observed in Fig. 4iii,
iv, is termed as an ‘F ion’ (Harvey et al., 2008) and
has a composition of GalNAc-GlcNAc-O-CH=CH-O-
(GalNAc + GlcNAc + 591), which comprises the Lac-
diNAc disaccharide and two carbon atoms from the
branching Man residue. Similarly, the N-glycan with
m/z 1205.02 was found to display antennae contain-
ing both the sialylated form of the LacdiNAc
(Neu5Ac-GalNAc-GlcNAc) and the sialylated LacNAc
(Neu5Ac-Gal-GlcNAc), observed as mass fragments of
m/z 696.21 and m/z 655.21, respectively, in the MS
spectra (Fig. 4v). This complex biantennary structure
was present in 93% of OC samples analysed in this
study. However, in the PC group, it was only found in
22% of samples.
2.3. The N-glycome discriminates OC from PC
When the relative abundance of each glycan structure
was compared between OC and PC, nine N-glycan
structures with specific glycan structural feature epi-
topes were identified to be statistically significant
(0.001 < P < 0.05) (Table 1). Three of these N-glycans
(m/z 1205.02, m/z 1059.42 and m/z 1079.92)
Fig. 4. Representative MS2 fragment ion spectra depicting the characterization of bisecting-biantennary and LacdiNAc-type N-glycan
structures in serous cancers. The neutral N-glycan m/z 913.92 with a composition of (Hex)1(HexNAc)3(dHex)1 +(Man)3(GlcNAc)2 consists of
two compositional isomers with separate retention times (i-insert). The first isomer was shown to elute at 38.5 min and the tandem MS
spectra corresponded to a bisecting GlcNAc-type core-fucosylated N-glycan with a monosaccharide composition of (Gal)1(GlcNAc)3
(Fuc)1+(Man)3(GlcNAc)2. This was confirmed by the presence of the diagnostic D-221
 cleavage ion at m/z 508.11. The second-eluting
isomer at 48 min consisted of a monosaccharide composition of (Gal)1 (GalNAc)1 (GlcNAc)2(Fuc)1+(Man)3(GlcNAc)2, which corresponded to a
‘LacdiNAc’-type N-glycan (ii-insert). The presence of the LacdiNAc antenna (GalNAcb1-4GlcNAc) was indicated by the B ion at m/z 405.11
and the 1,3A cross-ring cleavage ion at m/z 465.11 (‘F ion’). Several forms of LacdiNAc-type N-glycans identified in serous ovarian cancer
are illustrated for neutral LacdiNAc N-glycan with m/z 934.42 (iii), sialylated LacdiNAc N-glycan with m/z 1079.92 (iv) and sialylated
LacdiNAc/LacNAc N-glycan with m/z 1205.02 (v).
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contained LacdiNAc motifs with terminal sialylation
and were found to be significantly increased in OC.
Several other N-glycans upregulated in OC comprised
of hybrid N-glycans (m/z 937.32 and m/z 856.32)
and a bisecting-type sialylated biantennary N-glycan
(m/z 1286.02). An example of the expression levels of
the glycan with sialylated LacdiNAc (m/z 1205.02)
and a monosialylated hybrid glycan (m/z 937.32) in
OC compared to PC tissues is shown in Fig. 5A. On
the other hand, PC displayed a significant increase in
bisecting-type biantennary N-glycan (m/z 994.92),
agalactosylated biantennary N-glycan (m/z 739.32)
and monosialylated biantennary N-glycan (m/z
1038.92) (Table 1). ROC curves were generated for
N- and O-glycan relative ion intensities that were sig-
nificantly altered (P < 0.05) and the resulting AUC
was used as an indicator of the test accuracy. Based
on the ROC analysis, two individual N-glycan candi-
dates, m/z 1205.02 (AUC 0.93) and m/z 937.32
(AUC 0.89), were able to clearly discriminate OC from
PC (sensitivity: 86.7%, specificity: 92.3–100%), while
the combination of both glycans revealed a higher
AUC value of 0.95 and specificity (100%) (Fig. 5B,
Table 1). To further evaluate the discriminatory poten-
tial of the N-glycans, we performed RF and GLM
classification analysis on the total N-glycans released
from the serous cancer tissues. In total, four structures
were selected by GLM (m/z 1205.02, m/z 937.32, m/z
856.32 and m/z 994.92) and RF (m/z 937.32, m/z
856.32, m/z 739.32 and m/z 1079.92), respectively
(Table 1). The corresponding AUC for the four gly-
cans selected by GLM and RF were 0.97 (sensitivity:
93.3%, specificity: 100%) and 0.93 (sensitivity: 86.7%,
specificity: 100%), respectively (Fig. 5B). These results
indicate that that serous cancers of the ovary and peri-
toneum can be differentiated based on specific struc-
tures in their N-glycan profiles, and more importantly,
the selected glycan discriminants can be utilized as a
panel of biomarkers to distinguish between these can-
cers and thus, improve their diagnosis.
2.4. LacdiNAc-type glycans are elevated in
ovarian tissue-derived serous adenocarcinomas
The glycomic profiles of serous adenocarcinomas were
also re-evaluated based on the site from which the
tumour was surgically removed, that is ovary (left and
right ovary; n = 14), omentum (n = 11) and peri-
toneum (n = 3) (Table S1). We observed a high num-
ber of tissue-based discriminatory glycans in which
13 N-glycans (0.001 < P < 0.05) and three O-glycans
(P < 0.05) were identified, thereby discriminating
between the three tissue origins (Table 1).
Interestingly, two of the 13 N-glycan candidates that
contained the LacdiNAc structure (m/z 1205.02 and
m/z 1059.42) were strongly associated with ovarian-
derived cancer tissues, while the remaining two candi-
dates (m/z 1294.02 and m/z 1148.42) consisted of
branched N-glycans and were found to be statistically
elevated in the peritoneum-derived cancer tissues only
(Fig. 5C). We further performed a linear discriminant
analysis to visualize the discriminatory potential of
these glycans (Fig. 5D). Interestingly, the ovarian-
derived tissues were able to be separated based on the
glycan candidates selected by the RF feature selection
tool, while the peritoneum-derived tissue samples were
found to be clustered separately from the omentum-
and ovarian-derived tissues by the GLM feature selec-
tion tool (Fig. 5D), thereby indicating that serous can-
cers of ovarian and peritoneum origin, regardless of
their diagnosis, can also be distinguished based on
their respective tissue sites.
2.5. B4GALNT gene encoding
glycosyltransferases are implicated in the
distinction between OC and PC
Our glycan analysis on tissue samples revealed elevated
levels of LacdiNAc-type N-glycans in both OC-diag-
nosed and ovarian tissue-derived serous adenocarci-
noma samples. Glycan structures are often a
consequence of altered gene expression of the corre-
sponding glycosyltransferases responsible for their syn-
thesis (Anugraham et al., 2014; Jacob et al., 2014b;
Kawamura et al., 2008). We therefore accessed the tran-
scriptomic Tothill data set to identify the expression of
gene encoding glycosyltransferases potentially involved
in the proposed biosynthetic pathway for the synthesis
of LacdiNAc- and sialylated LacdiNAc-type structures
(Fig. 6A). In the Tothill data set, 232 patients fulfilled
the criteria for inclusion in our analysis and consisted of
199 clinically diagnosed OC and 33 PC patients. Upon
performing the initial gene expression analysis, we
hypothesized that both cancers may also be differenti-
ated based on their glyco-gene expression profiles.
The comparison between the ovarian and peritoneal
sites derived from the Tothill data set revealed five dif-
ferentially expressed (P < 0.05) glycosyltransferase
genes (Fig. 6B). Interestingly, two of the four possible
b1-4-acetylgalactosamine transferase genes
(B4GALNT1-4), B4GALNT3 and B4GALNT4, were
found to be significantly elevated (P < 0.05) in the
ovarian cancer tissues as compared to the peritoneum
(Fig. 6B). We have previously reported that N-glycans
with LacdiNAc motif were absent in human ovarian
surface epithelial cells (HOSE6-3 and HOSE17-1), but
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present in serous ovarian cancer cell lines (SKOV3 and
IGROV1) (Anugraham et al., 2014). Hence, coupled
with the new evidence from this study that the genes
B4GALNT3 and B4GALNT4 are correlated with the
presence of elevated LacdiNAc-type N-glycans on
ovarian cancer tissue-derived cell membranes, we sub-
sequently evaluated the glycan profiles of these serous
ovarian cancer cell lines, together with an additional
ovarian cancer cell line (EFO27) (Fig. 6C). In addi-
tion, a primary serous peritoneal cancer cell line
derived from a PC patient was also incorporated to
determine whether the presence of LacdiNAc is indeed
restricted to OC. To date, there is no serous peritoneal
cancer cell line commercially available (Jacob et al.,
2014c). Interestingly, both the N-glycans with sialy-
lated LacdiNAc motifs (m/z 1205.02 and m/z
1059.42) found to differentiate OC tissues were pre-
sent in the serous (SKOV3 and IGROV1) and muci-
nous (EFO27) ovarian cancer cell lines as depicted in
the extracted ion chromatograms (EIC) (Fig. 6C),
while no trace of these masses was observed in the pri-
mary serous peritoneal cancer cell culture (S129)
(Fig. 6C). We next established RT-qPCR for
B4GALNT3, B4GALNT4, ST6GAL2, ST3GAL4,
ST3GAL5 and three reference genes to quantify gene
expression in these cell lines (Table S4). In concor-
dance with our observations in the Tothill data set
comparing both tumour sites, the peritoneal cancer cell
line S129 showed lowest expression of these genes,
B4GALNT3 and B4GALNT4, compared to the nono-
varian and ovarian cancer cell lines (n = 7), therefore
reflecting the absence of LacdiNAc-type N-glycan
structures in this primary PC cell line (S129).
As for the high expression of a2,6-sialylated glycans
observed across both cancer types, we have previously
shown that ST6GAL1, responsible for the synthesis of
a2-6-linked N-glycans, was upregulated in all of the
four cancer cell lines previously tested (Anugraham
et al., 2014). The additional profiling of other sialyl-
transferase genes, ST6GAL2, ST3GAL4 and
ST3GAL5, was found to display varying gene expres-
sion levels between both cancer tissue types (Fig. 6B)
and across all tested ovarian cancer cell lines
(Fig. 6D). The differences in their expression are
potentially attributed to the regulation of these
enzymes across several glycan classes, including glycol-
ipids, which were not investigated in this study.
3. Discussion
The field of glycomics has become increasingly investi-
gated for its potential to unravel tumour-specific gly-
cans, which are associated with the cell surface ofT
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Fig. 5. Statistical evaluation of MS-profiled N-glycan candidates involved in the discrimination of serous cancers based on diagnosis and
tissue origin. (A) Box plot representing relative abundance of top two highest ranked N-glycan candidates that distinguish OC and PC based
on diagnosis. Data points for each serous cancer group [serous ovarian cancer (n = 14), serous peritoneal cancer (n = 14)] represent total
ion intensities of glycans in each category. (B) Receiver-operating characteristics curve for individual and feature selected glycans (refer to
Table 1 for values of discriminants). (C) Box plot representing highest ranked glycan mass relative ion intensities in cancer tissues derived
from omentum (OM), ovary (OV) and peritoneum (PE). Data points for each serous cancer group [ovarian (n = 14), omentum (n = 11),
peritoneum (n = 3)] are represented. (D) Linear discriminant analysis of glycan masses selected by t statistics (Top 4, RF and GLM). Wilks
lambda and corresponding P-value are provided in each scatter plot.
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ovarian cancer cells (Drake et al., 2010). In the pursuit
of discovering novel approaches to diagnosing the
diverse group of high-grade pelvic serous cancers, N-
and O-glycans were analysed from serous ovarian and
peritoneal cancers using a glycomics-based MS profil-
ing strategy, which has been successfully employed in
recent glycan biomarker studies (Alley et al., 2012;
Biskup et al., 2013; Kim et al., 2014). Specifically,
released membrane protein glycans were subjected to a
rigorous, structural MS-based characterization of gly-
cans and classification-based statistical tools were used
to assess the diagnostic performance of these glycans,
in addition to subsequent validation of specific glyco-
syltransferase genes implicated in their expression. To
the best of our knowledge, the structural analysis of
membrane protein glycosylation profiles in these
cancers represents the first study of its kind, with
regard to the characterization of discriminatory N-
and O-glycans of high-grade serous carcinomas. While
N-glycosylation profiles of ovarian cancer plasma sam-
ples have been previously studied and characterized
(Biskup et al., 2013; Mitra et al., 2013; Saldova et al.,
2007, 2008), the membrane glycomic profiles of OC
and PC tumour tissue samples have never been investi-
gated and compared simultaneously. This study also
showed the additional level of glycan profiling, namely
via the identification of compositional and structural
isomers, which is required for the determination of
low abundance discriminatory structures in serous can-
cers of differing cellular origins.
The specific cellular glycosylation and phenotypic
alterations that occur as a result of molecular genetic
Fig. 6. LacdiNAc is expressed in ovarian cancer cells and absent in normal surface epithelium as well as primary peritoneal cancer cells. (A)
Hypothetical synthesis pathway of LacdiNAc structures on N-glycoproteins. (B) Differentially expressed genes encoding glycosyltransferases
involved in synthesis of LacdiNAc structures (B4GALNT3 and B4GALNT4) and expression of sialyltransferase genes (ST6GAL2, ST3GAL4
and ST3GAL5) using transcriptomic data obtained from ovarian-derived (OV) and peritoneum-derived (PE) cancer tissues (Tothill data set).
Adjusted P-values are shown in each box plot. (C) Extraction ion chromatogram to show expression of LacdiNAc structures (m/z 1205.02
and m/z 1059.42) in normal epithelial cell lines (HOSE6-3, HOSE17-1), ovarian cancer cells [OVCAR3, SKOV3, IGROV1, A2780 and EFO27
(shift in retention time)] and primary peritoneal cells (S129). (D) Bar graph shows relative gene expression of relevant glyco-genes among
the tested cell lines. Gene expression is displayed relative to the cell line with lowest expression.
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mutations are unknown, particularly for these cancers.
As opposed to ovarian cancers which have been exten-
sively studied and characterized by high levels of
genetic instability and frequent mutations of TP53
(Jarboe et al., 2008; Kurman and Shih Ie, 2011), pri-
mary serous peritoneal cancers are less frequently
investigated (Jordan et al., 2008; Nik et al., 2014) and
are thought to share a common aetiology with ovarian
cancers based on their close histological and clinical
similarities (Kessler et al., 2013). It is therefore not
surprising that this close association between these ser-
ous cancers was also reflected in their membrane pro-
tein N- and O-glycomic profiles, as evidenced broadly
by the similar abundance when grouped into their gly-
can types. It is also interesting to note that the mem-
brane proteins of the tumour tissues displayed
abundant sialylation, a feature that has also been
observed in a recent study using high-resolution
MALDI-MS imaging (Everest-Dass et al., 2016). In
this study, the authors noted, however, that the mono-
and disialylated glycans were predominantly located in
the stromal region of ovarian tumour tissue cross-sec-
tions. Despite their similarities in overall glycan pro-
files, we demonstrate that the glycosylation of cell
membrane proteins of cancer cells is specific to the dis-
ease and the location where the tumour sample was
derived from. In particular, structurally related N-gly-
cans containing LacdiNAc-type motifs, which have not
been previously reported in membrane proteins of ser-
ous cancers, were found to be highly specific for OC.
This nonreducing end terminal group is rare on mam-
malian glycoproteins, and can be further modified with
sialic acid, fucose and sulfate (Hirano et al., 2014). In
agreement with this finding, we have previously identi-
fied LacdiNAc-type N-glycans in ovarian cancer cell
lines but not on normal HOSE cell line membrane
proteins (Anugraham et al., 2014) and this glycan
motif was also reported to be a tumour-specific glycan
in breast and ovarian cancer cell lines investigated in a
separate study (Guo and Abbott, 2015). In this tissue-
based study, we identified three sialylated LacdiNAc-
type N-glycans (m/z 1205.02, m/z 1059.42 and m/z
1079.92) that were capable of distinguishing OC from
PC, and these glycans, together with an additional
nonsialylated LacdiNAc-type N-glycan (m/z 913.92),
were all found to be associated with ovarian cancer-
derived tissues only. These findings point to the
increasing evidence that glycans are indeed tissue
specific and potentially offer a novel, yet exciting ave-
nue for targeted therapies/diagnostics.
Most mammalian N-glycans contain LacNAc
(Galb1-3/4GlcNAc) antennae, which form bianten-
nary, or branched tri- and tetra-antennary structures
that are usually capped by sialylation or extended to
form poly-LacNAc chains. The less common Lacdi-
NAc-type glycan, however, is synthesized by the action
of specific b4-GalNAc transferases (e.g. B4GALNT3
or B4GALNT4) (Gotoh et al., 2004; Sato et al., 2003).
Interestingly, while no trace of LacdiNAc N-glycans
was detected in the peritoneal cancer cell line, the non-
serous, mucinous-type ovarian cancer cell line EFO27
was also found to display this motif, thereby indicating
that LacdiNAc-type N-glycans could be largely associ-
ated with ovarian-derived cancer tissue. Nevertheless,
further analyses on nonserous-type cell lines need to
be performed to determine whether this epitope is non-
serous specific. It is also interesting to note that these
unique structures have never been reported in the sera
of patients with ovarian cancer (Alley et al., 2012;
Hua et al., 2013; Saldova et al., 2007), possibly due to
the low abundance of these N-glycan epitopes. In
regard to the glycosyltransferase expression extrapo-
lated from the Tothill data set, there seems to be an
increased expression of B4GALNT3 and B4GALNT4
in serous tumours derived from the ovary as compared
to the peritoneum, consistent with our findings in this
study. It is evident that a closer investigation into the
specific regulation of the LacdiNAc-type pathway in
high-grade serous cancers (HGSCs), particularly in
cancers originating from the ovary, is warranted.
The peritoneal origin of serous cancers remains
unclear as the normal peritoneum is composed of a
layer of mesothelium that forms the lining of the
abdominal cavity and can undergo malignant transfor-
mation to form a tumour entirely different from serous
peritoneal carcinoma (Seidman et al., 2011). In fact,
the serous-type epithelium from which serous peri-
toneal cancer is thought to be derived, positioned just
underneath the peritoneal surface, is ciliated and con-
sidered identical to that of the normal fallopian tube.
In regard to their glycan profiles, several glycosylation
features were shown to be upregulated in PC and
implicated in the distinction between ovary-, omen-
tum- and peritoneum-derived tissues. Most notably, in
peritoneal/omentum-derived serous cancer tissues,
structures such as the bisecting GlcNAc-type (m/z
994.92), branched N-glycans with increased Gal-
GlcNAc units (m/z 1294.02 and m/z 1148.42) and
sialylated core 2 O-glycan (m/z 1331.52) were all
found to be discriminatory. Bisecting GlcNAc N-gly-
can structures have been recently associated with sur-
vival in ovarian cancer and were found to result from
an epigenetically regulated MGAT3 expression (Kohler
et al., 2016). Our findings may indicate that bisecting
GlcNAc plays a role in ovarian cancer metastasis, pos-
sibly to various sites of the omentum/peritoneum. The
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appearance of these glycan structures with greater
complexity, that is branching patterns in the peri-
toneal/omentum-derived tissues, might be an adapta-
tion of cancer cells at the metastatic site to maintain
tumour growth, which has been demonstrated in the
case of brain metastasis for patients with breast cancer
(Bos et al., 2009).
In conclusion, our study provides the first molecular
evidence that OC and PC represent two distinct dis-
eases, reflected by differentially expressed glycans
attached to glycoproteins and their corresponding
altered glycosyltransferase gene levels. While at present
there is increasing evidence that HGSCs originate from
the fimbrial end of the tube, this is the first study per-
formed to clearly demonstrate that OC and PC need
to be regarded as distinct entities. It is possible that
the two cancer types may have been derived originally
from the fallopian tube and have metastasized and
adapted different tissue glycosylation pathways,
thereby displaying glycan features that are representa-
tive of their respective metastatic sites. Our preliminary
analyses of omentum/peritoneal samples from an ovar-
ian cancer case and ovarian-derived sample from peri-
toneal cancer case indicate that the glycan profiles
exhibit similarity based on their site of origin, indepen-
dent of the initial diagnosis. Ideally, knowledge of the
glycomics profiles of cancer tissue samples derived
from different locations including the metastasized
sites will also provide mechanistic insights in future.
Alternatively, it is possible that a specific subpopula-
tion of serous tubal intraepithelial cancer cells, with a
more mesenchymal-like differentiation, may trigger the
omental or peritoneal invasion rather than the ovarian.
The detection of these underlying morphological
changes is challenging and may further complicate the
clinical diagnosis of advanced-stage serous cancers, as
well as the subsequent treatment and management of
these aggressive cancers. It is therefore important that
future clinical considerations incorporate the origin of
each cancer type, and it is envisaged that the under-
standing of the differences in specific membrane glyco-
sylation determinants between these serous cancers
could provide alternative approaches for the disease to
be diagnosed and ultimately facilitate the development
of tailored ovarian cancer therapeutics.
4. Materials and methods
4.1. Biospecimens collection
Patients diagnosed with HGSCs were either admitted
with an adnexal mass to the Department of Gynecol-
ogy, University Hospital Zurich, Switzerland;
Limmattalspital, Schlieren, Switzerland; the Gyneco-
logical Cancer Centre of the Royal Hospital for
Women, Randwick, Australia; or the Gynecological
Cancer Centre of the John Hunter Hospital in New-
castle, Australia. All patients were prospectively
included after giving informed consent in accordance
with ethical regulations (SPUK, Canton of Zurich,
Switzerland, Hunter Area Research Ethics 04/04/07/
3.04; South Eastern Sydney Illawarra HREC/AURED
Ref: 08/09/17/3.02). Tissue and blood samples were
collected during surgery. All samples were selected
from chemona€ıve tumours. Tissue was kept in RNA
later solution (Life Technologies, Zug, Switzerland)
and stored at 80 °C until further use. The processing
of blood plasma samples was performed constantly on
ice within three hours after collection as previously
described (Jacob et al., 2011, 2012, 2014b). All clinico-
pathological data were incorporated in a specifically
designed in-house database (‘PEROV’; Microsoft
Access, Microsoft, USA). The diagnosis of these can-
cers as either serous ovarian (OC) or serous peritoneal
(PC) cancers and their corresponding histopathological
features were independently re-evaluated (Table S1).
4.2. Cancer tissue processing
Tissue processing was carried out using standardized
clinical and ethical protocols approved through inde-
pendent, board-approved institutions during the entire
collection period (Macquarie University-Ref: 26/09/11/
5201100778). Intact tissue samples (~ 40 mg) were
removed from RNAlater solution (Ambion, Thermo
Fisher Scientific, Waltham, MA, USA) using sterile
forceps, transferred to a Ultracell MC 0.45-l filter unit
placed in a 1.5-mL Eppendorf collection tube as previ-
ously described (Rader et al., 2008). An aliquot of
500 lL of ice-cold acetonitrile/water (80 : 20) was
added to the tissue samples and resulting RNAlater
ice crystals were precipitated by centrifugation. The
biphasic liquid in the collection tube was discarded
and several washings with acetonitrile/water were
repeated until there was no visible biphasic layer or ice
crystals observed.
4.3. Membrane protein extraction and glycan
release from membrane proteins
Tissues were washed in PBS prior to the Triton X-114-
based membrane protein extraction protocol carried
out as previously described (Lee et al., 2009). Briefly,
cut tissues were homogenized in lysis buffer and the
lysed cells in the supernatant were further sedimented
by ultracentrifugation. The membrane cell pellet was
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resuspended in Tris-binding buffer prior to the addi-
tion of Triton X-114 for phase partitioning of mem-
brane proteins. The membrane proteins in the lower
detergent layer were precipitated with acetone, pelleted
by centrifugation and solubilized in 8 M urea. N- and
O-Glycans were prepared as previously described (Jen-
sen et al., 2012). Briefly, membrane proteins and gly-
coprotein standard (10 lg of fetuin) were spotted onto
a polyvinylidene difluoride (PVDF) membrane, dried
overnight at room temperature and stained. Protein
spots were cut, placed in separate wells of a 96-well
microtiter plate and treated with PNGase F enzyme.
The released N-glycans were collected and treated with
ammonium acetate (pH 5.0) to regenerate the reducing
terminus and later reduced to alditols with sodium
borohydride. For O-glycans, the remaining PVDF
spots were treated with sodium borohydride and
released via reductive b-elimination. N- and O-Glycan
alditols were desalted using cation-exchange resin
beads (AG50W-X8) and residual borate was removed
by adding methanol. The purified N- and O-glycan
alditols were resuspended in milliQ water prior to mass
spectrometry analysis.
4.4. Mass spectrometric analysis of N- and O-
glycans
The separation of glycans was performed on a Hyper-
carb porous graphitized carbon capillary column
(5 lm Hypercarb KAPPA, 180 lm 9 100 mm;
Thermo Hypersil, Runcorn, UK) over a linear gradi-
ent for 85 min of 0–45% and 45 min of 0–90% (v/v)
acetonitrile/10 mM ammonium bicarbonate for N- and
O-glycans, respectively. The MS instrument used in
this study consisted of an ion trap mass spectrometer
(LC/MSD Trap XCT Plus Series 1100; Agilent Tech-
nologies, Santa Clara, CA, USA) connected to an ESI
source (Agilent 6330) and an Agilent autosampler
(Agilent 1100). The temperature of the transfer capil-
lary was maintained at 300 °C and the capillary volt-
age was set at 3 kV with helium as the collision gas.
The sample injection volume was 7 and 4 lL for N-
and O-glycans, respectively, and the flow rate was set
at 2 lLmin1. N- and O-Glycans were detected in
negative ionization mode as [M-H]1 and [M-2H]2
ions within the mass range of m/z 200–2200. MS data
were integrated using COMPASS DATA ANALYSIS version
4.0 software (Bruker Daltonics, Billerica, MA, USA).
Monoisotopic masses detected in negative mode were
assigned to possible monosaccharide compositions
using the GlycoMod tool (Cooper et al., 2001) avail-
able on the ExPASy server (http://au.expasy.org/tools/
glycomod) with a mass tolerance of  0.5 Da. Glycan
structures were identified based on manual annotation
of tandem MS fragmentation spectra and further char-
acterized with the aid of software-generated mass frag-
ments using GlycoWorkBench (Ceroni et al., 2008).
Verification of the proposed structures was also carried
out using UniCarb DB (Campbell et al., 2014b; Hayes
et al., 2011), a web-based LC-MS/MS database con-
taining fragmentation and retention times of previ-
ously reported N- and O-glycans (Campbell et al.,
2014a).
4.5. Cell culture
Ovarian cancer cell lines (IGROV1, A2780, SKOV3,
EFO27 and OVCAR3) and human ovarian surface
epithelial cells (HOSE6-3 and HOSE17-1) were grown
in RPMI-1640 media (Sigma-Aldrich, Buchs, Switzer-
land) supplemented with 10% (v/v) fetal bovine serum
(FBS; Sigma-Aldrich), penicillin (100 UmL1) and
streptomycin (100 lgmL1) (Sigma-Aldrich). They
were incubated at 37 °C in a 95% humidified atmo-
sphere containing 5% CO2. Cells were propagated at
about 80% confluence every two to three days and
tested routinely for mycoplasma infection (Uphoff and
Drexler, 2005). Cultured cells were harvested using
Cell Dissociation Solution nonenzymatic 19 (Sigma).
In regard to culture of primary serous peritoneal can-
cer cells, ascites was collected at the time of surgery,
centrifuged at 3000 g for 10 min and cultured in
DMEM/F12 (FBS, Sigma-Aldrich) supplemented with
20% (v/v) fetal bovine serum, penicillin (100 UmL1)
and streptomycin (100 lgmL1).
4.6. Reverse transcription quantitative
polymerase chain reaction (RT-qPCR)
In order to examine the expression of ‘glyco’ and ref-
erence genes, cells were grown in six-well plates
(NUNC, Thermo Fisher Scientific, Roskilde, Den-
mark). Cells were washed twice using DPBS (Gibco,
Sigma-Aldrich, Basel, Switzerland) and lysed, and total
RNA was isolated using NucleoSpin RNAII kit
(MACHEREY-NAGEL, Macherey-Nagel AG,
Oensingen, Switzerland). RNA was eluted in 50 lL
RNase-free water. After extraction and concentration,
total RNA was measured at A260/230 nm and A260/
280 nm using NanoDrop ND-1000 spectrophotometer
(Thermo Fisher Scientific). The RNA integrity of sam-
ples was confirmed by electropherograms (Agilent
2100 Bioanalyzer, Agilent Technologies (Schweiz) AG
Life Sciences & Chemical Analysis, Basel, Switzer-
land). An amount of 1 lg of total RNA was reverse-
transcribed using the iScript Reverse Transcription
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Supermix for RT-qPCR (Bio-Rad Laboratories AG,
Cressier, Switzerland) and complementary DNA
(cDNA) was stored at 20 °C until use. RT-qPCR
was performed in concordance to MIQE guidelines
(Bustin et al., 2009; Jacob et al., 2014b). qPCR was
performed on ‘glyco’ genes (B4GALNT3, B4GALNT4,
ST3GAL4, ST3GAL5 and ST6GAL2) and three puta-
tive reference genes (SDHA, YWHAZ and HSPCB)
(Tables S3 and S4). Primers specific to ‘glyco’ genes
were designed using QuantPrime (Arvidsson et al.,
2008). qPCR was performed on Applied Biosystems
ViiA™ Real-Time PCR System (Life Technologies) in
384-well microtitre plates (Life Technologies). To
achieve reliable gene expression patterns, all ‘glyco’
gene expressions were normalized against the logarith-
mic mean of the three reference genes.
4.7. Data acquisition and bioinformatical analysis
For the exploratory genetic analyses, we used a large
publicly available Affymetrix microarray data set
involving patients with OC and PC that provided asso-
ciated clinical information. As most data sets did not
pass the selection criteria of including both OC and
PC, the Tothill analysis was selected as it was the only
one that fulfilled these criteria (Tothill et al., 2008).
CEL files (Affymetrix U133, n = 285) and clinical data
were downloaded from the Gene Expression Omnibus
(GSE9899). The tumour location for sampling was
provided in the supplementary data of the original
publication (Tothill et al., 2008) and this information
was incorporated into our study. We included only
high-grade serous ovarian or peritoneal cancers of
advanced FIGO stages into our analysis to provide a
homogeneous group. Statistical analysis and figures
were obtained through the use of the software R ver-
sion 3.1.3 (www.R-project.org). Following R packages
were therefore applied: ‘cgdsr’, ‘catspec’, ‘com-
pareGroups’, ‘party’, ‘ggplot2’ and ‘Rcpp’. The
‘limma’ package from BIOCONDUCTOR open source soft-
ware for bioinformatics (R statistical software) was
used to identify differentially expressed genes between
study groups. P-values were adjusted by the Ben-
jamini–Hochberg false discovery rate method. In order
to perform stable feature selections for classification
and prediction of subgroups, two popular methods
were selected, random forest (RF) and penalized gen-
eralized linear model (GLM). RF was performed using
the package ‘randomForestSRC’. Penalized multino-
mial regression (Glmnet) was performed using the
package ‘glmnet’ within the R software. The compar-
ison of two algorithm guarantees a certain stability of
the selected features. Subsequent ROC curves with
corresponding AUC were estimated using the R pack-
age ‘pROC’. Additional linear discriminant analysis
(LDA) and multivariate ANOVA were performed to
test and visualize the performance of the feature selec-
tions (R package ‘lda’, ‘manova’). Survival analysis
was conducted using Kaplan–Meier curves with corre-
sponding log-rank tests (R package ‘Survival’). A P-
value < 0.05 was considered significant but interpreted
exploratory. All evaluations were made using R version
3.1.3 and BIOCONDUCTOR.
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